Details

Autor(en) / Beteiligte

• Biton, Jérôme
• Mansuet-Lupo, Audrey
• Pécuchet, Nicolas
• Alifano, Marco
• Ouakrim, Hanane
• Arrondeau, Jennifer
• Boudou-Rouquette, Pascaline
• Goldwasser, François
• Leroy, Karen
• Goc, Jeremy
• Wislez, Marie
• Germain, Claire
• Laurent-Puig, Pierre
• Dieu-Nosjean, Marie-Caroline
• Cremer, Isabelle
• Herbst, Ronald
• Blons, Hélène
• Damotte, Diane

Titel

TP53, STK11 , and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma

Ist Teil von

• Clinical cancer research, 2018-11, Vol.24 (22), p.5710-5723

Ort / Verlag

United States: American Association for Cancer Research

Erscheinungsjahr

2018

Quelle

Elektronische Zeitschriftenbibliothek

Beschreibungen/Notizen

• By unlocking antitumor immunity, antibodies targeting programmed cell death 1 (PD-1) exhibit impressive clinical results in non-small cell lung cancer, underlining the strong interactions between tumor and immune cells. However, factors that can robustly predict long-lasting responses are still needed. We performed in-depth immune profiling of lung adenocarcinoma using an integrative analysis based on immunohistochemistry, flow-cytometry, and transcriptomic data. Tumor mutational status was investigated using next-generation sequencing. The response to PD-1 blockers was analyzed from a prospective cohort according to tumor mutational profiles and PD-L1 expression, and a public clinical database was used to validate the results obtained. We showed that distinct combinations of , and mutations were major determinants of the tumor immune profile (TIP) and of the expression of PD-L1 by malignant cells. Indeed, the presence of mutations without co-occurring or alterations ( -mut/ - -WT), independently of mutations, identified the group of tumors with the highest CD8 T-cell density and PD-L1 expression. In this tumor subtype, pathways related to T-cell chemotaxis, immune cell cytotoxicity, and antigen processing were upregulated. Finally, a prolonged progression-free survival (PFS: HR = 0.32; 95% CI, 0.16-0.63, < 0.001) was observed in anti-PD-1-treated patients harboring -mut/ - -WT tumors. This clinical benefit was even more remarkable in patients with associated strong PD-L1 expression. Our study reveals that different combinations of , and mutations, together with PD-L1 expression by tumor cells, represent robust parameters to identify best responders to PD-1 blockade. .